蛋白酶体抑制剂治疗的胃肠道毒性
Jay Shah1, Samanthika Devalaraju1, Elliot Baerman1
1Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA.
Journal of cancer research and clinical oncology
|July 5, 2024
概括
蛋白质酶抑制剂 (PI) 可以导致癌症患者的胃肠道问题. 与博特佐米布或卡菲尔佐米布相比,伊克萨佐米布的发病时间较晚,腹较少,大多数患者出现轻度症状.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白酶体抑制剂 (PI) 在治疗血液性恶性瘤方面至关重要.
- 胃肠道的不良反应是PI治疗的重大限制.
- 关于与PI相关的特定胃肠道毒性存在有限的证据.
研究的目的:
- 为了评估与蛋白酶体抑制剂相关的胃肠道不良事件.
- 为了比较博雷佐米布,卡菲尔佐米布和伊克萨佐米布之间的胃肠毒性.
主要方法:
- 在第三级护理癌症中心接受PI治疗的癌症患者的回顾性研究.
- 分析PI相关的胃肠道不良事件的临床特征.
- 包括973名PI暴露和便研究的患者 (2017年1月至2022年12月).
主要成果:
- 20%的患者 (193/973) 经历了与PI相关的胃肠道毒性.
- 腹是最常见的症状 (88%的受影响患者).
- 与博特佐米布 (58天) 和卡菲尔佐米布 (89天) 相比,伊克萨佐米布的症状出现间隔较长 (313天),腹发病率较低.
结论:
- 与PI相关的胃肠道毒性因表现和过程而异.
- 尽管住院和复发率很高,但大多数患者表现出较轻微的疾病.
- 队列显示了有利的结果,没有长期的胃肠道后果.
相关概念视频
The Proteasome
827
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
827
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
158
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
158
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
192
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
192
Toxic Reactions: Overview
964
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
964
Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
The Proteasome Structure
730
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
730


